Response Genetics, Inc. is a molecular diagnostics company that develops and provides biomarker-based testing services to guide personalized cancer treatment. The company operates a CLIA-certified laboratory in Los Angeles, California, offering comprehensive genomic analysis designed to identify molecular targets and predict patient response to oncology therapies. Through its proprietary testing platform, Response Genetics aims to help oncologists tailor treatment regimens based on the genetic profile of a patient’s tumor, ultimately improving clinical outcomes and reducing healthcare costs associated with ineffective therapies.
Response Genetics’ core product suite includes tests for non–small cell lung cancer, melanoma, breast cancer and colorectal cancer, among other solid tumors. Each assay leverages next-generation sequencing and quantitative PCR technologies to detect mutations, gene amplifications and other genomic alterations that inform therapeutic decision making. In addition to its U.S. operations, the company supports clients in Europe via a dedicated subsidiary, maintaining compliance with international quality standards and fostering collaborations with regional healthcare institutions.
Founded in 2000, Response Genetics has pursued strategic partnerships with pharmaceutical and biotechnology companies to co-develop companion diagnostics and to validate biomarkers in clinical trial settings. The company’s work has contributed to several peer-reviewed publications and has been incorporated into clinical practice guidelines for targeted cancer therapies. Over the years, Response Genetics has expanded its service offerings to include customized assay development and translational research support for drug discovery programs.
Response Genetics is led by a management team with extensive experience in molecular diagnostics, oncology drug development and laboratory operations. The leadership group oversees ongoing assay development, regulatory compliance and expansion of its testing network. With a focus on precision medicine and continued investment in advanced genomic technologies, Response Genetics seeks to strengthen its role in the evolving landscape of cancer diagnostics and to support the broader adoption of personalized treatment approaches worldwide.
AI Generated. May Contain Errors.
Free RGDXQ Stock Alerts